# A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

> **NCT02573259** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 147 (actual)

## Conditions studied

- Part 1
- MELANOMA
- SCCHN
- OVCA
- SARCOMA
- OTHER SOLID TUMORS
- Part 1 and 2
- NSCLC
- UROTHELIAL CARCINOMA

## Interventions

- **DRUG:** PF-06801591
- **DRUG:** PF-06801591

## Key facts

- **NCT ID:** NCT02573259
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-10
- **Primary completion:** 2020-11-19
- **Final completion:** 2020-11-19
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2021-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573259, "A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02573259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*